Cargando…

Current small cell lung cancer treatment in China

BACKGROUND: The treatment status of small cell lung cancer (SCLC) in Mainland China has never been reported; therefore, this study is the first multicenter survey investigating the status of epidemiology and treatment options of SCLC in Mainland China. METHODS: Two questionnaires were designed to ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yuankai, Xing, Puyuan, Fan, Yun, Zhang, Xin, Hu, Chengping, Wang, Caixia, Liu, Xiaoqing, Chen, Xiaoxia, Zhou, Jianying, Wang, Mengzhao, Wu, Meina, Han, Baohui, Fan, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448384/ https://www.ncbi.nlm.nih.gov/pubmed/26273367 http://dx.doi.org/10.1111/1759-7714.12218

Ejemplares similares

Medical management of lung cancer: Experience in China
por: Shi, Yuankai, et al.
Publicado: (2015)

Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study
por: Xing, Puyuan, et al.
Publicado: (2022)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
por: Si, Xiaoyan, et al.
Publicado: (2019)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Epidemiology of lung cancer in China
por: Cao, Maomao, et al.
Publicado: (2018)

Clinical experiences with molecular targeted therapy in lung cancer in China
por: Wang, Yan, et al.
Publicado: (2015)

Early detection of lung cancer: Low-dose computed tomography screening in China
por: Zhao, Shi-Jun, et al.
Publicado: (2015)

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study
por: Xing, Puyuan, et al.
Publicado: (2019)

Artificial intelligence in lung cancer: current applications and perspectives
por: Chassagnon, Guillaume, et al.
Publicado: (2022)

Value of ablation therapy in the treatment of lung metastases
por: Qi, Han, et al.
Publicado: (2017)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
por: Song, Peng, et al.
Publicado: (2020)

Current status and perspectives of spread through air spaces in lung cancer
por: Ikeda, Toshihiro, et al.
Publicado: (2021)

A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients
por: Mo, Hongnan, et al.
Publicado: (2016)

Role of circulating tumor DNA in the management of early‐stage lung cancer
por: Zhao, Heng, et al.
Publicado: (2018)

The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer
por: Feng, Yu, et al.
Publicado: (2022)

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
por: Araki, Taisuke, et al.
Publicado: (2023)

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
por: Han, Baohui, et al.
Publicado: (2018)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2022)

Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer
por: Xu, Jin, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related adverse events: A review of case reports
por: Si, Xiaoyan, et al.
Publicado: (2020)

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma
por: Liu, Yutao, et al.
Publicado: (2020)

Commentary on “Penile augmentation with injectable hyaluronic acid gel: an alternative choice for small penis syndrome”
por: Xing, Monica, et al.
Publicado: (2022)

Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study
por: Shi, Yuankai, et al.
Publicado: (2015)

Nerve biopsy: Current indications and decision tools
por: Nathani, Dev, et al.
Publicado: (2021)

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
por: Mu, Yuxin, et al.
Publicado: (2019)

Penile rehabilitation following prostate cancer treatment: review of current literature
por: Clavell-Hernandez, Jonathan, et al.
Publicado: (2015)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
por: Xing, Puyuan, et al.
Publicado: (2021)

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer
por: Lu, Shun, et al.
Publicado: (2022)

Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer
por: Wang, Haiyang, et al.
Publicado: (2018)

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
por: Liang, Hongge, et al.
Publicado: (2019)

Synthetic biology: From the first synthetic cell to see its current situation and future development
por: Zhang, LiuYan, et al.
Publicado: (2011)

Current treatment of benign biliary strictures
por: Costamagna, Guido, et al.
Publicado: (2013)

Genetic contributions to stuttering: the current evidence
por: Frigerio‐Domingues, Carlos, et al.
Publicado: (2017)

Primary stroke prevention in China – a new approach
por: Feigin, Valery L., et al.
Publicado: (2015)

Gemcitabine combined with cisplatin as adjuvant chemotherapy for non‐small cell lung cancer: A retrospective analysis
por: Ma, Di, et al.
Publicado: (2017)

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association
por: Ba, Yi, et al.
Publicado: (2020)

Real‐world treatment and prognostic factors for survival in ALK+ non‐small cell lung cancer (NSCLC) patients with brain metastases in China
por: Li, Na, et al.
Publicado: (2022)

Development of medical treatment for eye injuries in the mainland of China over the past decade
por: Wang, Chang-Guan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n2js8ppacc1e8qffnkjrnr7v8l